Breaks Categories: News

TuesdayJul 18, 2023 1:02 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Arbitration Panel Finding in Syneos Health (NASDAQ: SYNH) Proceeding

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is reporting that an arbitration panel has found that Syneos Health (NASDAQ: SYNH) failed to use commercially reasonable efforts in conducting its trial for FSD 201. According to the announcement, Syneos Health filed an arbitration proceeding against FSD Pharma in 2022. Syneos claimed that FSD Pharma owed Syneos Health $3,915,388.69 in damages as well as interest on that amount in relation to a failed phase 2 FDA trial…

Continue Reading

MondayJul 17, 2023 1:12 pm

BioMedNewsBreaks – Institute of Biomedical Research Corp. (MRES) Unveils Meticulously Crafted Line of Teas Sourced from Kenya

Institute of Biomedical Research (OTC: MRES) (doing business as M2Bio Sciences) is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence and evidence-based sustainable products and solutions. M2Bio Sciences today announced the forthcoming launch of a captivating line of teas sourced from the scenic gardens of Kenya. The meticulously crafted collection provides not only an exquisite sensory experience but also delivers exceptional medicinal health benefits. “We are delighted to introduce our exceptional line of purple, white and green teas from Kenya,” said Jeff Robinson, CEO of M2Bio Sciences. “Our…

Continue Reading

WednesdayJul 12, 2023 11:32 am

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Financial Results for Fiscal 2023

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, today announced its financial results for the fiscal year ended March 31, 2023 (“Fiscal 2023”). “Fiscal 2023 was characterized by remarkable growth and progress as we continue to advance our drug formulations through FDA trials,” said Ram Mukunda, CEO of IGC. “IGC-AD1 is delivering strong results as it progresses through phase 2B trials. We are delighted with the positive headway we are making in clinical trials, and we remain confident in the potential of IGC-AD1 to be a groundbreaking therapy, with the potential to treat Alzheimer’s and to manage devastating symptoms…

Continue Reading

TuesdayJul 11, 2023 2:06 pm

BioMedNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Announces New Findings to Be Presented at Annual AAIC

INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced new findings from data to be presented at the annual Alzheimer’s Association International Conference (“AAIC”). Slated to take place in Amsterdam, Netherlands, AAIC is the largest medical meeting focused on Alzheimer’s disease (“AD”). “One of the difficulties in developing drugs for AD is the inability to quantify the disease and measure changes at the tissue or microstructure level. The current approaches to measure brain changes utilize imaging techniques that measure the whole brain,” said RJ Tesi,…

Continue Reading

TuesdayJul 11, 2023 1:31 pm

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Expands C-Suite to Welcome Key GBB Drink Lab Execs

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced that, along with the asset purchase agreement for the company’s purchased and provisional patents, two GBB Drink Lab executives will join Jupiter Wellness’ C-suite. Josh Wagner, the former U.S. director of sales for Anheuser Busch, where he led a $12 billion business with a 72 person sales team to their best performance since 2009, will serve as Jupiter Wellness’ chief revenue officer. In addition, David Sandler, the former COO and CSO of several supplement brands that exceeded $75 million in revenue, will serve as the company’s…

Continue Reading

TuesdayJul 11, 2023 1:13 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Bell2Bell Podcast

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in the latest episode of the Bell2Bell Podcast. The podcast is part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. BiondVax CEO Amir Reichman joined the program to discuss the company’s recent achievements. “At the end of 2022, we did a round of financing and raised about $8 million. We also started the negotiations to in-license the next antibody from the Max Planck Institute – namely the antibody for…

Continue Reading

MondayJul 10, 2023 11:41 am

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Moves to Acquire ‘Safety Shot’ – the World’s First Rapid Blood Alcohol Detox Drink

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness, today announced it has executed an asset purchase agreement with GBB Drink Lab Inc. Under the agreement, all operating assets related to GBB Drink Lab, including the revolutionary Safety Shot beverage, will belong to Jupiter Wellness. Safety Shot, which is protected by a number of issued and pending patents covering composition of matter and methods of use, creates a new product category for rapid alcohol detoxification in the fast-growing hangover remedy market. “The world-first breakthrough nature of Safety Shot and the market it addresses are a tremendous opportunity…

Continue Reading

FridayJul 07, 2023 10:47 am

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Secures $12M Line of Credit to Strengthen Efforts in Alzheimer’s Research

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has secured a $12 million revolving line of credit from the Hong Kong Branch of O-Bank Co. Ltd. The funding will support IGC’s working capital needs primarily related to its Alzheimer’s research. Bradbury Asset Management (Hong Kong) Limited, a Hong Kong headquartered financial institution managing approximately $2 billion in assets, has collateralized cash assets in support of the line of credit. This follows the recent investment of $3 million in IGC led by four investment funds managed by Bradbury through a private placement, highlighting continued support for the company. “We are…

Continue Reading

ThursdayJul 06, 2023 3:53 pm

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces $3M Common Stock Private Placement

IGC Pharma (NYSE American: IGC), a company that develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer's disease, period cramps (dysmenorrhea), premenstrual syndrome ("PMS") and chronic pain, has received strategic investment support. According to an announcement from the company, it has received investments from four funds managed by Bradbury Asset Management (Hong Kong) Limited, a leading asset management firm with more than $2 billion in managed assets. The announcement also noted that additional contributions were received from three unrelated investors. In total, the company has received an estimated $3 million in gross proceeds. “The…

Continue Reading

ThursdayJul 06, 2023 1:29 pm

BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Unique Treatment Paradigm Featured in Bell2Bell Podcast

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, was featured in the latest episode of Bell2Bell Podcast. The podcast is part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Rodney Varner, GNPX’s chairman, president and CEO, and Ryan Confer, the company’s CFO, joined the program to discuss the journeys that led them to Genprex and the promise of the company’s drug development pipeline. “As I learned more and more about the technology, it became a passion of mine, as well,” said Confer. “What we’re…

Continue Reading